Acrivon Therapeutics (ACRV) Corporate presentation summary

Strategic focus and technology platform

• AP3 platform leverages AI-driven proteomics for rational drug design and precise clinical development, enabling exact matching of drug mechanisms to disease-driving pathways in oncology and inflammation.

• Proprietary tools include a data portal, interactome, and protein activity predictor, supporting drug discovery and biomarker development.

• Headquarters in Boston with a proteomics hub in Medicon Valley, leveraging access to leading biotech clusters.

• Founded in 2018, IPO in 2022, with a leadership team experienced in drug development, clinical trials, and business operations.

Pipeline and clinical programs

• Lead asset ACR-368 (CHK1/2 inhibitor) shows durable monotherapy activity in multiple cancers, especially endometrial cancer, with favorable safety and absence of severe non-hematological toxicities.

• OncoSignature biomarker test prospectively predicts patient response, enabling stratified and biopsy-independent trial arms.

• Registrational intent Phase 2b trials in endometrial cancer, including serous all-comer arms, with interim analysis and data updates expected in 2H 2026.

• ACR-2316 (WEE1/PKMYT1 inhibitor) in Phase 1/2, demonstrating potent anti-tumor activity and synergy with checkpoint inhibitors and TOPOI payload ADCs.

• CDKII inhibitor (ACR-6840) nominated as a development candidate, targeting aggressive AML and other indications.

Clinical data and efficacy

• ACR-368 achieved 39% ORR and 80.6% DCR in biomarker-positive endometrial cancer patients; higher ORR (44%) in those with ≤2 prior lines of therapy.

• Serous endometrial cancer all-comer population showed 52% ORR, addressing a high unmet need with limited treatment options.

• Deep, rapid responses observed in aggressive serous tumors, including complete resolution of hepatic metastases.

• ACR-368 demonstrates synergy with anti-PD-L1 and TOPOI inhibitors, supporting combination strategies for future trials.

• ACR-2316 shows robust preclinical and early clinical activity across tumor types, including lung cancer, with 79% DCR in heavily pretreated patients.